Practice question

Answer the question and get instant feedback.

Hard"Finerenone reduces CKD progression/CV events in T2D with albuminuria on ACEI/ARB when SGLT2i are not tolerated. DPP‑4/TZDs lack renal outcome benefits; discontinuing RAAS blockade is harmful."Nephrology"hard"

A 67-year-old with T2D has CKD G3b A3. He cannot tolerate SGLT2 inhibitors. What kidney-protective therapy should be considered?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.